Dr. Moon was in the first class of accredited headache fellowships in the United States. Since leaving Mayo Clinic , Dr. Moon has been a national leader in the field of headache and facial pain. He has conducted clinical trials and consulted on the development of AIMOVIG (Amgen), VYEPTI (Lundbeck), AJOVY (Teva), UBRELVY (Abbvie), ZAVZPRAT (Biohaven), and BOTOX (Allergan). He is also a national consultant on NURTEC (Biohaven), EMGALITY (Lilly), CAMBIA (formerly Depomed), TRUDHESA (Impel), QULIPTA (Abbvie), QUDEXY (Upsher Smith), TROKENDI (Supernus), ONZETRA (Avanir) and REVYOW (Lilly). 

Early drug development has allowed our patients early access to the newest concepts and latest therapies. However, DNC understands that treatment needs to be catered to the patient and sometimes minimalist therapies can work such as vitamin and supplemental therapies.